Penske orders 750 Freightliner Cascadias

Avatar photo

PORTLAND, Ore. — Penske Truck Leasing has placed an order for 750 Freightliner Cascadias with the company’s BlueTec selective catalytic reduction (SCR) technology, Daimler Trucks North America has announced.

DTNA points out the purchase makes Freightliner the majority supplier of EPA2010-compliant tractors to Penske Truck Leasing.

The order includes: 50 Cascadia 113-inch single-axle day cab tractors equipped with Detroit Diesel DD13 engines; 450 Cascadia 125-inch tandem-axle day cab tractors equipped with DD13engines; and 250 Cascadia 125-inch tractors with a 72-inch raised roof and Detroit Diesel DD15 engines.

Penske previously ordered 132 Freightliner Business Class M2 medium-duty trucks with SCR-equipped Cummins engines and 50 Freightliner Cascadia tractors with a mix of Cummins ISX, Detroit Diesel DD13 and DD15 engines, Daimler announced.

“Based on our own research and field testing, we determined that SCR emissions technology was the right fit for Penske and our customers to comply with the 2010 standards,” said Marc Althen, senior vice-president, administration and procurement for Penske. “And, when coupled with the advanced performance of the Cascadia, our customers get a powerful and efficient business tool that positively impacts their bottom line.”

“We are pleased to build upon our long-term relationship with Penske Truck Leasing by supplying the majority of their 2010 solution,” added Mark Lampert, senior vice-president, sales and marketing for Daimler Trucks North America.

Avatar photo

Truck News is Canada's leading trucking newspaper - news and information for trucking companies, owner/operators, truck drivers and logistics professionals working in the Canadian trucking industry.


Have your say


This is a moderated forum. Comments will no longer be published unless they are accompanied by a first and last name and a verifiable email address. (Today's Trucking will not publish or share the email address.) Profane language and content deemed to be libelous, racist, or threatening in nature will not be published under any circumstances.

*